NCT07155122View on ClinicalTrials.gov

Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2030

Conditions
Small-Cell Carcinoma of the Esophageal
Interventions
DRUG

Drug: Serplulimab

serplulimab Serplulimab , 300mg, D1, intravenous drip , Q3W.

DRUG

Drug: Etoposide

Etoposide, 60-100 mg/m², D1-3 or D1-5, intravenous drip, Q3W

DRUG

Drug: Chemotherapy

Cisplatin, 50-75 mg/m², D2, intravenous drip, Q3W. Or Carboplatin, AUC 5, D2, intravenous drip, Q3W.

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV